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AbstrAct
Pulmonary function tests are valuable investigations in 
the management of patients with suspected or previously 
diagnosed respiratory disease. They aid diagnosis, 
help monitor response to treatment and can guide 
decisions regarding further treatment and intervention. 
The interpretation of pulmonary functions tests requires 
knowledge of respiratory physiology. In this review we 
describe investigations routinely used and discuss their 
clinical implications.
IntroductIon
Pulmonary function tests (PFTS) are an important tool in 
the investigation and monitoring of patients with respiratory 
pathology. They provide important information relating to the 
large and small airways, the pulmonary parenchyma and the 
size and integrity of the pulmonary capillary bed. Although 
they do not provide a diagnosis per se, different patterns of 
abnormalities are seen in various respiratory diseases which 
helps to establish a diagnosis. We describe the indications for 
performing PFTS, describe abnormal results and correlate 
these with underlying pathology.
GenerAl consIderAtIons And normAl 
vAlues
Guidelines for performing and interpreting PFTS have been 
published both by the European Respiratory and American 
Thoracic Societies1-6. Indications for performing PFTS are 
listed in table 17. Performing PFTS is generally safe but 
specific contraindications exist. These are listed in table 27. 
PFTS are effort dependent and therefore patient cooperation 
and understanding in performing the tests is essential in 
obtaining optimal results. Suboptimal results may be obtained 
in patients who have chest or abdominal pain or from patients 
who do not fully understand directions given to perform the 
tests.
Patients with active respiratory infections such as tuberculosis 
are not precluded from having PFTS however the tests should 
ideally be deferred until the risk of cross contamination is 
negligible. If patients with infectious disease must undergo 
testing then extra precautions in addition to the standard 
decontamination of equipment may be necessary. This may 
include performing PFTS at the end of the day to allow 
Table 1
Indications for Pulmonary Function Tests
1.  Investigation of patients with symptoms/signs/
investigations that suggest pulmonary disease e.g.
•	 Cough
•	 Wheeze
•	 Breathlessness
•	 Crackles
•	 Abnormal chest x-ray
2.  Monitoring patients with known pulmonary disease 
for progression and response to treatment e.g.
•	 Interstitial fibrosis
•	 COPD
•	 Asthma
•	 Pulmonary vascular disease
3.  Investigation of patients with disease that may have a 
respiratory complications e.g.
•	 Connective tissue disorders
•	 Neuromuscular diseases
4.  Preoperative evaluation prior to e.g.
•	 Lung resection
•	 Abdominal surgery
•	 Cardiothoracic surgery
5.  Evaluation patients a risk of lung diseases e.g.
•	 Exposure to pulmonary toxins such a radiation, 
medication, or environmental or occupational 
exposure
6.  Surveillance following lung transplantation to assess 
for
•	 Acute rejection
•	 Infection
•	 Obliterative bronchiolitis
Table 2
Contraindications to performing PFTS7
Myocardial infarction within the last month
Unstable angina
Recent thoraco-abdominal surgery
Recent ophthalmic surgery
Thoracic or abdominal aneurysm
Current pneumothorax
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disassembly and disinfection of equipment, undertaking 
tests in the patients’ room rather than the lung function 
laboratory and reserving equipment for sole use in patients 
with infections1.
A sitting position is typically used at the time of testing to 
prevent the risk of falling and injury in the event of a syncopal 
episode, although PFTS can be performed in the standing 
position.  Patients are advised not to smoke for at least one 
hour before testing, not to eat a large meal two hours before 
testing and not to wear tight fitting clothing as under these 
circumstances results may be adversely effected1. False teeth 
are left in place unless they prevent the patient from forming 
an effective seal around the mouth piece.
Normal or predicted ranges of values are obtained from large 
population studies of healthy subjects. Values are taken for 
people matched for age, height, sex and where appropriate 
ethnicity. PFTS should be performed three times to ensure that 
the results are reproducible (less than 200ml variation) and 
accurate. Dynamic studies are performed first (spirometry, 
flow volume curves, peak expiratory flow rates), followed 
by lung volumes, bronchodilator testing and finally diffusion 
capacity. Each of these aspects of PFTS will now be reviewed 
in more detail.
spIrometry
Spirometry is the most frequently used measure of lung 
function and is a measure of volume against time. It is a 
simple and quick procedure to perform: patients are asked 
to take a maximal inspiration and then to forcefully expel air 
for as long and as quickly as possible (a forced vital capacity 
manoeuvre- figure 1). Measurements that are made include
•	 Forced expiratory volume in one second (FEV1)
•	 Forced vital capacity (FVC)
•	 The ratio of the two volumes (FEV1/FVC)
Spirometry and the calculation of FEV1/FVC allows the 
identification of obstructive or restrictive ventilatory defects. 
A FEV1/FVC < 70 % where FEV1 is reduced more than FVC 
signifies an obstructive defect (figure 2). Common examples 
of obstructive defects include chronic obstructive pulmonary 
disease (COPD) and asthma. The FEV1 can be expressed as a 
percentage of the predictive value which allows classification 
of the severity of the impairment (table 3)8. An FEV1/FVC 
> 70% where FVC is reduced more so than FEV1 is seen 
in restrictive defects such as interstitial lung diseases (e.g. 
idiopathic pulmonary fibrosis) and chest wall deformities 
(figure 3). 
Flow volume curves
Flow volume curves are produced when a patient performs a 
maximal inspiratory manoeuvre which is then followed by a 
maximal expiratory effort. A graph is produced with a positive 
expiratory limb and a negative inspiratory limb (figure 4). The 
maximal flow rate during expiration can also be measured 
(peak expiratory flow rate PEFR). Furthermore the maximal 
flow rates between 25%-75% of the vital capacity (FEF25-
Table 3
Severity of airflow obstruction based on percentage (%) 
predicted forced expiratory volume in 1 second (FEV1).
FEV1 % predicted Stage
>80% Mild
50-79% Moderate
30-49% Severe
<30% Very severe
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Fig 3. Spirometry in restrictive lung disease.
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75%) can also be measured and these provide important 
information regarding small airway function. 
With knowledge of the expected appearance of the flow 
volume loop in a normal patient, important information can 
be obtained from the morphology of the curve in patients 
with suspected respiratory disease. Patients with obstructive 
lung diseases with reduced expiratory flow in the peripheral 
airways typically have a concave appearance to the descending 
portion of the expiratory limb (figure 5) rather than a straight 
line. In patients with emphysema the loss of elastic recoil 
and radial support results in pressure dependent collapse of 
the distal airways with more pronounced “scalloping” of the 
expiratory limb. Even if the flow volume loop morphology 
is normal, a reduction in PEFR may be an indication of 
asthma with early airways obstruction. Similarly a reduction 
in FEF25-75% indicates small airways obstruction. This can 
also occur in patients with asthma with a normal PEFR, and is 
useful in providing a better overall picture of asthma control. 
It is also helpful in monitoring response to treatment and this 
may be particularly important for patients being considered 
for general anaesthetic and surgical intervention.In restrictive 
defects the expiratory limb has a convex or linear appearance 
because flow rates are preserved but the problem relates to a 
parenchymal disorder e.g. lung fibrosis which reduces lung 
volumes.
Flow volumes curves are helpful in the detection of large 
airway abnormalities. Typically intra-thoracic large airway 
obstruction (e.g. from a lower tracheal or bronchial tumour 
figure 7) results in flattening of the expiratory limb alone 
with preservation of the inspiratory limb (figure 8). Normally 
in expiration there is a rise in intrathoracic pressure, which 
is transmitted to the intrathoracic airway causing some 
narrowing of the airway. The presence of an obstructing lesion 
coupled with a rise in intrathoracic pressure during expiration 
results in a more pronounced and pathological reduction 
in airflow through the obstructed or partially occluded 
intrathoracic airway. 
In f ixed extra-thoracic large airway obstruction (e.g. 
vocal cord paralysis or tracheal stenosis figure 9) there is 
symmetrical flattening of both the inspiratory and expiratory 
limb as airflow is limited in both directions and is not affected 
significantly by intrathoracic pressure changes (figure 10)9.
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Figure 4: Normal flow volume curve 
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Figure 5: Flow volume curve in obstructive lung disease e.g. COPD 
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Figure 6: Flow volume curve in restrictive lung disease e.g. interstitial lung disease. 
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Figure 8: Flow volume curve seen with intra-thoracic airway obstruction 
 
 
 
 
 
 
 
 
Fig 6. low volume curve in restrictive lung disease e. .  
interstitial lung disease.
Fig 7. A bronchial carcinoma obstructing the right main bronchus. 
© The Ulster Medical Society, 2011.
Pulmonary Function Tests 87
www.ums.ac.uk
bronchodIlAtor testInG
The diagnostic hallmark of asthma is the presence of 
reversible airways obstruction. Patients with controlled or 
stable asthma may have apparently normal spirometry and 
flow volume curves. It is therefore useful to see if there is 
any change in the airway indices following the administration 
of a bronchodilator such as 2.5mg of nebulised salbutamol. 
A positive response in adults is defined as a 12% increase 
in baseline (pre bronchodilator) FEV1 with an increase 
of 200mls or more following the administration of a 
bronchodilator. A negative test does not mean a patient will 
not derive any benefit from a trial of bronchodilator therapy 
such as inhaled salbutamol or corticosteroids. It is therefore 
important to use the patient’s history and examination in 
addition to the above in formulating a diagnosis and treatment 
plan. In this regard home peak flow charts are helpful. 
Bronchial challenge testing may also be considered where 
a 20% fall in FEV1 in response to small doses of inhaled 
bronchoconstrictors such as methacholine is indicative of 
asthma.
lunG volumes
Static lung volumes are measured with the use of whole body 
plethysmography in an airtight body box. Other techniques 
that can be used to measure static lung volumes included 
nitrogen washout or helium dilution4. They cannot be 
measured by spirometry. 
In body plethysmography, the patient sits inside an airtight 
box, inhales or exhales to a particular volume (usually FRC), 
and then a shutter drops across their breathing tube. The 
subject makes respiratory efforts against the closed shutter. 
Measurements are based on Boyle’s law which states that 
at constant temperature the volume of a given mass of gas 
varies inversely with pressure. Therefore the increase in their 
chest volume slightly reduces the box volume (the non-person 
volume of the box) and thus slightly increases the pressure 
in the box. Static lung volumes can be obtained either by 
measuring the changes in pressure in a constant volume box 
or volume in a constant pressure box4.
resIduAl volume 
Residual volume (RV) is the amount of air remaining in 
the lungs after a maximal expiration (normally 500mls). 
In patients with obstructive lung diseases where there is 
incomplete emptying of the lungs and air trapping, RV may 
be significantly increased. Patients with high RV who require 
surgery and mechanical ventilation require high peri-operative 
inflation pressures. This increases the risk of barotrauma, 
pneumothorax, infection and reduced venous return due to 
high intra thoracic pressures. The RV can also be expressed 
as a percentage of total lung capacity and values in excess of 
140% significantly increase the risks of these complications.7 
Patients referred for lung volume reduction surgery typically 
have RV in excess of 180% predicted.
totAl lunG cApAcIty
Total lung capacity (TLC) is the total volume of air in the 
lungs after a maximal inspiration. It is the sum of RV and 
vital capacity (the difference in volume between maximal 
inspiration and maximal expiration). TLC may be increased 
in patients with obstructive defects such as emphysema and 
decreased in patients with restrictive abnormalities including 
chest wall abnormalities and kyphoscoliosis.
FunctIonAl resIduAl cApAcIty
Functional residual capacity (FRC) is the volume of air in 
the lungs following normal expiration. Patterns of abnormal 
FRC are similar to abnormalities given above for TLC and RV.
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Figure 6: Flow volume curve in restrictive lung disease e.g. interstitial lung disease. 
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Figure 8: Flow volume curve seen with intra-thoracic airway obstruction 
 
 
 
 
 
 
 
 
Fig 8. Flow volume curve seen with intra-thoracic airway 
obstruction.
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Figure 10: Flow volume curve seen with fixed extra-thoracic airway obstruction 
 
 
 
 
 
 
 
 
 
 
Fig 10. Flow volume curve seen with fixed extra-thoracic  
airway obstr ction
Fig 9. Tracheal stenosis seen at rigid bronchoscopy.
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dIFFusIon cApAcIty
The measurement of diffusion capacity (DLCO also known 
as transfer factor) gives important information regarding the 
integrity and size of the alveolar blood membrane. It measures 
the diffusion of gas across the alveolar membrane which is 
determined by the surface area and integrity of the alveolar 
membrane and the pulmonary vascular bed. Normally the 
value is corrected for the patient’s haemoglobin (DLCOc). 
DLCOc is measured using carbon monoxide gas, which is 
soluble and binds to haemoglobin with its uptake limited by 
diffusion only. It is measured by a single breath technique 
where 10% helium and 0.3% carbon monoxide are rapidly 
inspired, held for 10 seconds and then expired with the 
measurement of the remaining carbon monoxide. Comparison 
of the inspired and expired CO fractions allows calculation 
of DLCO3.
DLCOc is determined by the surface area of the alveolar 
membrane and as such, is impaired in conditions where the 
surface area is reduced e.g. pulmonary fibrosis, emphysema 
or pulmonary emboli. The transfer coefficient (KCO) is 
DLCOc corrected for alveolar volume. In patients with a 
pneumonectomy DLCOc will be reduced due to the loss of 
approximately half of the surface area of alveolar membrane 
but KCO will be normal as the remaining lung is normal with 
normal function of the alveolar blood membrane. Similarly 
variation can be seen in diseases that effect the lungs in a 
heterogeneous manner e.g. COPD or alpha 1 antitrypsin 
emphysema. In COPD the upper lobes tend to be preferentially 
damaged whereas in alpha 1 antitrypsin deficiency the lower 
lobes are predominantly involved. Therefore DLCOc will be 
lower than KCO. Pulmonary emboli should be considered in 
patients with an isolated reduction in DLCOc without any 
other obvious respiratory cause.
respIrAtory muscle FunctIon
A number of diseases such as motor neurone disease can 
result in respiratory muscle weakness, which can ultimately 
lead to respiratory failure. These diseases can effect not only 
chest wall muscles but also the diaphragm which is the major 
inspiratory muscle. Serial measurements of vital capacity 
may be necessary to detect deterioration in lung function in 
patients with neuromuscular disease such as Guillan Barre 
Syndrome. Once the vital capacity falls below 1 litre in such 
patients mechanical ventilatory support may be indicated. 
Other measures of respiratory muscle function include 7:
Inspiratory mouth pressures – a measure of inspiratory 
muscle function in which subjects generate as much 
inspiratory pressure as possible against a blocked mouth 
piece10. The pressure generated (maximum inspiratory 
pressure MIP) is therefore largely a function of the inspiratory 
respiratory muscles rather than lung volumes which do not 
change significantly during the test10. A normal value is 
approximately 100 cm of water. Values of 80 cm of water or 
more exclude any significant inspiratory muscle weakness 11.
expiratory mouth pressures- a measure of expiratory 
respiratory muscle function where patients generate a 
maximal expiratory pressure (MEP) against a blocked 
mouthpiece (a valsalva manoeuver) at TLC. The range of 
normal values is wide and results should be compared with 
published data 11.
erect and supine vital capacity- in normal subjects there 
is a 5% decrease in vital capacity in the supine position. A 
fall of 25% or more may indicate diaphragmatic paralysis 
and further confirmatory tests e.g. ultrasound screening of 
diaphragm may be necessary.
ArterIAl blood GAses
Arterial blood gas sampling provides important information 
on gas exchange and oxygen delivery to the tissues. Type 1 
respiratory failure is defined as a partial pressure of oxygen 
(PaO
2
) < 8 kPa with normal partial pressure of carbon 
dioxide (PaCO
2
). Causes of type 1 respiratory failure include 
pneumonia and pulmonary embolism. Type 2 respiratory 
failure occurs when hypoxia is accompanied by hypercapnia 
(PaCO
2 
> 6.5 kPa). This is seen in ventilatory failure and 
examples of causes include respiratory muscle weakness 
and COPD. Type 2 respiratory failure may also occur in 
patients with advanced type 1 respiratory failure as they tire 
and develop ventilatory failure. Such patients may require 
ventilatory support in the form of non-invasive or invasive 
ventilation.
overnIGht oxImetry
Patients who complain of excessive daytime sleepiness (as 
measured by the Epworth Sleepiness Scale) and snoring 
with or without witnessed apnoeas should be investigated for 
obstructive sleep apnoea (OSA). Overnight oximetry can be 
used initially in the assessment of OSA. Typically 10 oxygen 
desaturations per hour of more than 4% would be considered 
to be indicative of OSA. Normal overnight oximetry does 
not exclude OSA and more detailed sleep studies including 
polysomnography should be performed in patients where 
there is a high clinical suspicion of OSA.
cArdIopulmonAry exercIse testInG
Cardiopulmonary exercise testing (CPET) involves 
patients exercising on a treadmill or cycle ergometer with 
measurements of variables such ventilation, heart rate, 
oxygen uptake (V’O
2
) and cardiac output. This allows causes 
for a reduced exercise tolerance to be identified, which may 
be due to ventilatory abnormalities in those with chronic 
lung disease or impaired cardiac output in patients with 
cardiac disease. It may be useful in patients who complain of 
excessive breathlessness and in whom investigations such as 
echocardiogram and pulmonary functions tests are normal. A 
V’O
2
 peak standardized by body mass below 80% predicted 
is considered to be abnormal12.
usInG pulmonAry FunctIon tests In pre-
operAtIve evAluAtIon oF pAtIents
It is important to address a number of concerns in evaluating 
a patient prior to surgery. These include determining if a 
patient is 7:
•	 Fit for a general anesthetic
•	 Appropriate for the planned surgical procedure
•	 Requires further treatment for any underlying respiratory 
problems (which may or may not have been identified 
prior to the evaluation). 
These decisions are typically made by anaesthetists, with input 
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from respiratory physicians and intensive care physicians7. In 
a patient with chronic respiratory disease it is important to 
identify how much of their breathlessness is caused by their 
lung disease particularly if the patient is being considered for 
cardiac surgery. If their breathlessness is predominantly due 
to respiratory disease, this will not necessarily be improved 
by any corrective cardiac surgery. Surgery may also not be 
justified if their respiratory disease carries a poor prognosis 
in itself.  It is important to try and identify any contributing 
causes for breathlessness particularly in patients with multiple 
co morbidities so that these can be addressed, investigated 
and treated as appropriate. This short history illustrates the 
point. A 71-year-old male smoker with COPD was referred 
for consideration regarding aortic valve replacement for 
aortic stenosis (AS). Physical examination revealed features 
compatible with COPD and AS but in addition he had a 
disproportionately loud pulmonary component to the second 
heart sound and a right ventricular heave. A ventilation/
perfusion scan was ordered which confirmed multiple 
pulmonary emboli and abdominal imaging diagnosed a renal 
tumour involving the inferior vena cava. Cardiac surgery was 
postponed. 
It is important to identify patients with respiratory problems 
that are at increased risk of peri-operative complications 
such as respiratory infection including ventilator acquired 
pneumonia, atelectasis, acute lung injury and prolonged 
respiratory failure with may all result in difficulty weaning 
from mechanical ventilation post operation. Risk factors for 
peri-operative pulmonary complications include increased 
age, COPD and smoking13, 14. The risk of complications 
is also related to the surgical site and its proximity to the 
diaphragm with increased complications seen following aortic 
aneurysm repair, and thoracic and upper abdominal surgery13. 
Procedures longer than 3 hours in duration are also associated 
with increased risk. Although there are no clear guidelines 
regarding the routine use of pre-operative PFTS, they are 
generally used in the assessment of symptomatic patients 
undergoing major thoraco-abdominal surgery. It should be 
remembered that pulmonary complications may occur in 
patients without risk factors and that strategies to reduce the 
risk of these complications such as smoking cessation and 
lung expansion techniques (e.g. deep breathing exercises) 
should be used in all patients with particular attention given 
to those at increased risk.
Patients with chronic respiratory disease or with impairment 
of PFTS at pre operative evaluation are challenging to 
assess. We recommend that where there is doubt regarding 
suitability for a general anaesthetic appropriate advice from 
anaesthetists, intensive care and respiratory physicians is 
sought and efforts to optimise the patient as much as possible 
are made.
pulmonAry FunctIon tests In pAtIents 
underGoInG lunG resectIon
Resection of primary lung cancers in the form of lobectomy 
or pneumonectomy remains the treatment of choice in patients 
with early stage disease15. Many patients with lung cancer 
will also have COPD and it is important to try and determine 
the effect of lung resection on these patients both in terms 
of postoperative complications and long term disability16, 17. 
The British Thoracic Society guidelines advise that 
pneumonectomy can be considered in  patients with FEV1 
> 2.0 L and lobectomy if FEV1> 1.5 L in the absence of 
any interstitial lung disease or unexpected disability due to 
shortness of breath15. As absolute values may be lower in 
older patients and women, patients are generally considered 
suitable for resection if FEV1> 80% predicted and DLCO > 
80% predicted18. In patients with borderline lung function the 
post operative predicted FEV1 and DLCO can be calculated 
either with knowledge of the number of lung segments to 
be resected or through quantitative lung perfusion scanning. 
Patients with a post operative predicted FEV1 or DLCO < 
40% are deemed at high risk of peri-operative death and 
complications17. Further investigations including CPET may 
be necessary for further risk stratification.
PFTS are used in the assessment of patients for lung 
transplantation. Patients with PFTS below 30% predicted may 
potentially be considered for lung transplantation assuming 
no other contraindications are present19, 20.
rIGht heArt cAtheterIsAtIon
Chronic respiratory diseases may result in pulmonary 
hypertension and eventually right-sided cardiac failure and 
death. Pulmonary hypertension should be considered in 
patients with symptoms or signs of right-sided cardiac failure 
or perhaps with more dyspnoea than expected on the basis of 
their PFTS and clinical presentation.
A Doppler trans thoracic echocardiogram is a useful non-
invasive tool in screening for pulmonary hypertension. 
Right heart catheterisation is considered the gold standard 
tool and can diagnose pulmonary hypertension with the 
measurement of a mean pulmonary artery pressure > 
25mmHg21. In experienced centres it can be performed safely 
and provide information on pulmonary haemodynamics 
including cardiac output, pulmonary vascular resistance and 
an approximation of mean left atrial pressure by measuring 
the mean pulmonary capillary wedge pressure22. Patients with 
pulmonary hypertension are at increased risk of peri-operative 
complications including pulmonary hypertensive crises 
where an acute rise in pulmonary pressures results in right 
ventricular failure and a subsequent fall in cardiac output. 
Knowledge of pulmonary haemodynamics allows careful 
pre-emptive management of these problems. Furthermore 
some patients with co existing pulmonary hypertension 
and cardiac or pulmonary disease may benefit from specific 
targeted therapy for their pulmonary hypertension e.g. using 
sildenafil23-28.
conclusIon
Pulmonary function tests are an important tool in the 
assessment of patients with suspected or known respiratory 
disease. They are also important in the evaluation of patients 
prior to major surgery. Interpretation of the tests, which 
requires knowledge of normal values and appearance of flow 
volume curves, must be combined with the patient’s clinical 
history and presentation.
The authors have no conflict of interest.
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